Literature DB >> 14697260

NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice.

Jennie L Williams1, Khosrow Kashfi, Nengtai Ouyang, Piero del Soldato, Levy Kopelovich, Basil Rigas.   

Abstract

The chemopreventive effect of nitric oxide-releasing aspirin (NO-ASA) against gastrointestinal tumorigenesis was evaluated in Min (APC(Min/+)) mice. NO-ASA consists of a traditional ASA that bears covalently attached to it an NO-releasing moiety. Four groups (N=10) of six-week-old female C57BL/6J APC(Min/+) and the corresponding C57BL/6J(+/+) wild type mice were treated either with vehicle or NO-ASA 100 mg/kg/day intrarectally for 21 days. There were no signs of overt toxicity including gastrointestinal toxicity from NO-ASA. Vehicle treated Min mice had 24.7 +/- 3.8 tumors (mean +/- SEM) and NO-ASA treated Min mice had 10.1 +/- 1.4 tumors (59% reduction; P<0.001). Wild type mice showed no tumors. NO-ASA did not affect cell proliferation in small intestinal mucosa, determined by immunohistochemical staining for PCNA. Our findings establish the strong inhibitory effect of NO-ASA in intestinal carcinogenesis in the Min mouse and suggest that this agent merits further evaluation as a chemopreventive agent against colon cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14697260     DOI: 10.1016/j.bbrc.2003.12.015

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

Review 1.  The Wnt signaling pathway in cancer.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-24       Impact factor: 6.312

2.  Nitric oxide-releasing sulindac is a novel skin cancer chemopreventive agent for UVB-induced photocarcinogenesis.

Authors:  Sandeep C Chaudhary; Tripti Singh; Puneet Kapur; Zhiping Weng; Aadithya Arumugam; Craig A Elmets; Levy Kopelovich; Mohammad Athar
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-27       Impact factor: 4.219

3.  Inhibition of matrix metalloproteinase-9 by a barbiturate-nitrate hybrid ameliorates dextran sulphate sodium-induced colitis: effect on inflammation-related genes.

Authors:  Shane O'Sullivan; Jun Wang; Maria T Pigott; Neil Docherty; Noreen Boyle; Samuel Kana Lis; John F Gilmer; Carlos Medina
Journal:  Br J Pharmacol       Date:  2017-02-24       Impact factor: 8.739

Review 4.  The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.

Authors:  Basil Rigas; George J Tsioulias
Journal:  J Pharmacol Exp Ther       Date:  2015-04       Impact factor: 4.030

Review 5.  Pharmacologic Manipulation of Wnt Signaling and Cancer Stem Cells.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Methods Mol Biol       Date:  2017

6.  Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo.

Authors:  Zhiquan Zhang; Liqun Huang; Wenping Zhao; Basil Rigas
Journal:  Cancer Res       Date:  2010-03-09       Impact factor: 12.701

7.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

Review 8.  The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.

Authors:  Khosrow Kashfi
Journal:  Biochem Pharmacol       Date:  2018-02-14       Impact factor: 5.858

9.  Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.

Authors:  Carmela De Santo; Paolo Serafini; Ilaria Marigo; Luigi Dolcetti; Manlio Bolla; Piero Del Soldato; Cecilia Melani; Cristiana Guiducci; Mario P Colombo; Manuela Iezzi; Piero Musiani; Paola Zanovello; Vincenzo Bronte
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

Review 10.  Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly.

Authors:  Peter R Holt; Peter Kozuch; Seetal Mewar
Journal:  Best Pract Res Clin Gastroenterol       Date:  2009       Impact factor: 3.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.